NCT06168305View on ClinicalTrials.gov

Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery Disease

Enrolling by invitationOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
Percutaneous Coronary InterventionMultivessel Coronary Artery Disease
Interventions
DEVICE

GENOSS® DES Sirolimus Eluting Coronary Stent System

The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.

Trial Locations (1)

08308

Korea University GURO Hospital, Seoul

All Listed Sponsors
lead

Genoss Co., Ltd.

INDUSTRY